Discovering The Potential Therapeutic Targets of Protein-Arginine Deiminase (PADI3)

Target Name: PADI3

NCBI ID: G51702

PADI3

Discovering The Potential Therapeutic Targets of Protein-Arginine Deiminase (PADI3)

Protein-arginine deiminase (PADI3) is a protein that is expressed in various tissues throughout the body, including the brain, heart, kidneys, and liver. It is a member of the superfamily of aryl hydrocarbon (AI) hydrolases, which are a group of enzymes that are involved in the breakdown of aromatic amino acids, such as arginine and tyrosine.

PADI3 is highly conserved, with sequence identity of up to 96% between different species. It is expressed in a variety of tissues and organs, including the brain, where it has been shown to be highly expressed in the cerebral cortical cortical tissue. PADI3 is also expressed in the heart, kidneys, and liver, where it is involved in the regulation of various physiological processes, including inflammation, fibrosis, and stress responses.

One of the unique features of PADI3 is its catalytic mechanism. Unlike other AI hydrolases, which use a Michaelis-Menten kinetics to describe the binding of substrate to the enzyme, PADI3 uses a unique mechanism called the \"one-dimensional\" binding model. This model allows PADI3 to bind to its substrate in a specific sequence, rather than using a pre-determined binding site, as is the case with other AI hydrolases. This unique mechanism allows PADI3 to have a highly specific and efficient catalytic activity.

In addition to its unique catalytic mechanism, PADI3 has also been shown to have a number of potential drug-like properties. For example, PADI3 has been shown to be a potent inhibitor of the angiogenic factor, PDGF-BB, which promotes the formation of new blood vessels and is often associated with tissue damage and disease. Additionally, PADI3 has been shown to be a potent inhibitor of the fibroblastic growth factor, FGF-1, which promotes the production of new cells and is often associated with tissue fibrosis.

Furthermore, PADI3 has also been shown to have neuroprotective properties. Studies have shown that PADI3 is expressed in the brain and that it has been shown to protect against neurotoxins, such as urethane and glutamate, which are often associated with neurodegenerative diseases. Additionally, PADI3 has been shown to protect against oxidative stress, which is often associated with neurodegenerative diseases, by regulating the expression of genes involved in the detoxification of oxidants.

Despite its potential drug-like properties, PADI3 is not yet a validated drug target. However, research into PADI3 and its potential drug-like properties is ongoing, and there is significant interest in using PADI3 as a new therapeutic target for a variety of neurodegenerative diseases.

One approach to targeting PADI3 is to use small molecules to inhibit its catalytic activity. This would be a novel and effective way to treat neurodegenerative diseases, as current treatments for these diseases are often limited to supportive care and have limited efficacy. Additionally, because PADI3 is highly conserved across different species, it is a promising target for the development of new therapeutic compounds that can be used to treat a wide range of neurodegenerative diseases.

Another approach to targeting PADI3 is to use antibodies to block its catalytic activity. This would be a highly effective way to treat neurodegenerative diseases, as current treatments for these diseases are often limited to supportive care and have limited efficacy. Additionally, because PADI3 is highly conserved across different species, it is a promising target for

Protein Name: Peptidyl Arginine Deiminase 3

Functions: Catalyzes the deimination of arginine residues of proteins

The "PADI3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PADI3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets